Cargando…

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartoli, Francesco, Riboldi, Ilaria, Bachi, Bianca, Calabrese, Angela, Moretti, Federico, Crocamo, Cristina, Carrà, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005219/
https://www.ncbi.nlm.nih.gov/pubmed/33810033
http://dx.doi.org/10.3390/jcm10061303
_version_ 1783672084178665472
author Bartoli, Francesco
Riboldi, Ilaria
Bachi, Bianca
Calabrese, Angela
Moretti, Federico
Crocamo, Cristina
Carrà, Giuseppe
author_facet Bartoli, Francesco
Riboldi, Ilaria
Bachi, Bianca
Calabrese, Angela
Moretti, Federico
Crocamo, Cristina
Carrà, Giuseppe
author_sort Bartoli, Francesco
collection PubMed
description Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders.
format Online
Article
Text
id pubmed-8005219
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80052192021-03-29 Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review Bartoli, Francesco Riboldi, Ilaria Bachi, Bianca Calabrese, Angela Moretti, Federico Crocamo, Cristina Carrà, Giuseppe J Clin Med Review Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders. MDPI 2021-03-22 /pmc/articles/PMC8005219/ /pubmed/33810033 http://dx.doi.org/10.3390/jcm10061303 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bartoli, Francesco
Riboldi, Ilaria
Bachi, Bianca
Calabrese, Angela
Moretti, Federico
Crocamo, Cristina
Carrà, Giuseppe
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title_full Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title_fullStr Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title_full_unstemmed Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title_short Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
title_sort efficacy of cannabidiol for δ-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005219/
https://www.ncbi.nlm.nih.gov/pubmed/33810033
http://dx.doi.org/10.3390/jcm10061303
work_keys_str_mv AT bartolifrancesco efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT riboldiilaria efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT bachibianca efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT calabreseangela efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT morettifederico efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT crocamocristina efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview
AT carragiuseppe efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview